Altre lingue Betta Pharmaceuticals Co., Ltd.

Azioni

300558

CNE100002DD9

Prezzo di chiusura Shenzhen S.E. Altri mercati azionari 00:00:00 23/04/2024			Variaz. 5gg	Var. 1 gen.
38,65 ^CNY	+0,91%		+2,77%	-25,02%

19/04	Betta Pharmaceuticals Co., Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
2023	Betta Pharmaceuticals Co., Ltd. riporta i risultati degli utili per i nove mesi conclusi il 30 settembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	19/04
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	04/01
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.	01/08/23
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance	05/07/23
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing	09/06/23
Betta Pharmaceuticals Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 15 June 2023	08/06/23
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China	30/05/23
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC	30/05/23
C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	30/05/23
Betta Pharmaceuticals Co., Ltd. Approves Cash Dividend for the Year of 2022	16/05/23
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23
Betta Pharmaceuticals Co., Ltd. Announces Profit Distribution Proposal for 2022	24/04/23
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23/04/23
Betta Pharmaceuticals Gets Nod to Start Clinical Trial of Tumor Drug in China	14/03/23
Betta Pharmaceuticals Co., Ltd. cancelled the transaction announced on June 13, 2022	10/01/23
Betta Pharmaceuticals Co., Ltd. Approves Board Elections	28/12/22
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	24/08/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Betta Pharmaceuticals Co., Ltd.

Azioni

300558

CNE100002DD9

Altre lingue

Filtri